Sublingual THC-CBD reduces myofascial pain in small Brazil study
Mar 6th 2026
A 20-patient prospective crossover study published in Clinics found daily sublingual cannabis extract with equal THC and CBD substantially reduced myofascial pain and improved jaw function in Temporomandibular Disorder, with researchers urging larger randomized trials.
- Prospective crossover study of 20 patients in São Paulo compared 90 days of placebo followed by 90 days of sublingual cannabis extract with equal THC and CBD.
- Dose started at 2 mg/day and increased by 2 mg each week to 10 mg/day by week five.
- Patients had a nearly 4-point reduction in TMD-related pain on a 0 to 10 scale during cannabis treatment.
- Cannabinoid therapy was linked to improved jaw function in opening, protrusion, and laterality versus placebo.
- Authors call for larger randomized trials to confirm findings, and prior placebo-controlled work in Poland found topical CBD gels also reduced TMD symptoms.